entertainment -WSS

entertainment

author：knowledge 2025-09-02 09:56:16 - browse：2

Yichuan Cao/Sipa USA via AP Images

Gilead Sciences said Monday that Trodelvy, its “smart-bomb” medicine that combines an antibody with chemotherapy, did not significantly extend the lives of patients with metastatic non-small cell lung cancer when given after a first treatment failed.

The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike.

Drugs like Trodelvy, known as antibody drug conjugates, are one of the hottest areas in oncology. The idea is that these medicines combine an antibody, which is triggered when it binds to a protein on a cancer cell, with a “payload” of chemotherapy that poisons the cancer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How one patient went off dialysis — and others can too

focus

leisure time

WSS

Paxlovid should be available without a positive Covid test

Listen: Who gets the credit for GLP

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Biogen shutters digital health group, ends Apple study, in cost cutting move

FDA advisers vote against ALS treatment from BrainStorm

Democrats decry new health bill for going easy on private equity

leisure time

entertainment

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

'Investigate these claims': UFO transparency at center of House hearing

Medical records are filled with copy

'Investigate these claims': UFO transparency at center of House hearing

Cancer drug shortages should be causing more outrage

How the Dana

Medicare details structure of new drug price negotiation program

Mindstrong's demise and the future of mental health care

Bright Health sells Medicare Advantage business to Molina

Data show record exodus of life scientists from academia

focus

Medicare drug price negotiation program allowed for now

Rise in cancer among younger people worries and puzzles doctors

What it's like to live with paralysis for one psychologist

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Would Medicare drug price negotiations stall in a shutdown?

A new crop of companies is reshaping the health data economy

explore

focus

leisure time

hotspot